TABLE 3.
Subjects with treatment-emergent adverse events
| Body system and adverse event | No. of subjects in treatment group with adverse event
|
|
|---|---|---|
| Moxifloxacin, 400 mg (n = 10) | Placebo (n = 5) | |
| Any adverse event | 8 | 4 |
| Whole body (total) | 3 | 2 |
| Abdominal pain | 1 | 1 |
| Arm pain | 1 | 0 |
| Headache | 2 | 1 |
| Digestive system (total) | 6 | 2 |
| Diarrhea | 3 | 2 |
| Dry mouth | 2 | 0 |
| Dyspepsia | 1 | 0 |
| Flatulence | 1 | 0 |
| Nausea | 3 | 1 |
| Tooth pain | 1 | 0 |
| Nervous system, dizziness | 1 | 1 |
| Respiratory tract, rhinitis | 3 | 0 |
| Skin and appendages, acne | 1 | 0 |